Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
19.34 SEK | +0.73% | +6.03% | +25.10% |
08/05 | Transcript : Orexo AB, Q1 2024 Earnings Call, May 08, 2024 | |
17/04 | Orexo Expands, Extends US Patent for Nasal Anaphylaxis Treatment | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+25.10% | 60.88M | |
+8.33% | 72.94B | |
-10.36% | 5.07B | |
+51.87% | 4.78B | |
+4.51% | 3.9B | |
-14.26% | 2.56B | |
+21.32% | 2.42B | |
-23.94% | 2.39B | |
+20.02% | 2.18B | |
+3.66% | 1.65B |
- Stock Market
- Equities
- ORX Stock
- News Orexo AB
- Orexo Obtains First US Patent for Nasal Epinephrine Product